Explore

Rapid Read Rapid Read
CMMI Launches ACCESS Model to Transform Chronic Care with Technology

CMMI Launches ACCESS Model to Transform Chronic Care with Technology

The Center for Medicare and Medicaid Innovation (CMMI) has introduced the Advancing Chronic Care with Effective Scalable Solutions (ACCESS) Model, a 10-year initiative aimed at enhancing chronic condition management through technology and artificial intelligence. This program, announced in December, seeks to provide stable payments for technology used in treating conditions such as diabetes, hypertension, and depression. The ACCESS Model aligns with the Centers for Medicare and Medicaid Services' goal of integrating all traditional Medicare beneficiaries into accountable care relationships by 2030. It introduces a new category of Medicare Part B providers, known as ACCESS organizations, which will receive payments based on outcomes rather than specific activities. The model is designed to break down barriers to digital health access for Medicare patients, offering a 'Medicare app store' for beneficiaries to choose suitable digital health programs.
Rapid Read Rapid Read
Legal Challenge to CMS Hemp Strategy Raises Concerns Over FDA Authority

Legal Challenge to CMS Hemp Strategy Raises Concerns Over FDA Authority

A federal lawsuit in the U.S. District Court for the District of Columbia is challenging the legality of the Centers for Medicare & Medicaid Services' (CMS) Beneficiary Engagement Incentive (BEI) model. This program allows the furnishing of certain hemp-derived cannabinoid products to Medicare beneficiaries without U.S. Food and Drug Administration (FDA) approval. The case, Smart Approaches to Marijuana (SAM) et al. v. Robert F. Kennedy Jr. et al., questions whether CMS can introduce cannabinoid products into Medicare-connected environments without the traditional FDA approval process. Critics argue that this policy shift undermines the established sequence of science, clinical trials, FDA approval, and coverage integration, potentially signaling that clinical evidence is optional.
Trendline Trendline
Insulet Corporation Launches Pivotal Study for Automated Insulin Delivery System for Type 2 Diabetes

Insulet Corporation Launches Pivotal Study for Automated Insulin Delivery System for Type 2 Diabetes

Insulet Corporation Launches Pivotal Study for Automated Insulin Delivery System for Type 2 Diabetes
Rapid Read Rapid Read
Healthcare Waste Drives U.S. Debt, Calls for Policy Reform

Healthcare Waste Drives U.S. Debt, Calls for Policy Reform

The U.S. healthcare system is facing scrutiny for its significant contribution to the national debt due to wasteful spending. According to a recent analysis, a substantial portion of healthcare expenditures does not translate into improved health outcomes. This inefficiency is largely attributed to unnecessary services and administrative overhead, which account for about 25% of total healthcare spending. The analysis suggests that up to 52% of healthcare spending could be saved by focusing on preventive care rather than reactive treatment. The current system often rewards volume over value, leading to overtreatment and increased costs. This situation is exacerbated by 'defensive medicine,' where fear of litigation prompts excessive testing and procedures. The report highlights the need for evidence-based care and informed patient choices to reduce waste and improve outcomes.
Trendline Trendline
BrainScope Appoints David Wingate to Boost Commercial Operations and Market Expansion

BrainScope Appoints David Wingate to Boost Commercial Operations and Market Expansion

BrainScope Appoints David Wingate to Boost Commercial Operations and Market Expansion
Rapid Read Rapid Read
Insulet Launches Study for Automated Insulin Delivery System for Type 2 Diabetes

Insulet Launches Study for Automated Insulin Delivery System for Type 2 Diabetes

Insulet Corporation has initiated a pivotal study for its fully closed-loop automated insulin delivery (AID) system for type 2 diabetes. The study, named EVOLVE, aims to demonstrate the safety and efficacy of this system compared to standard therapy. The system is designed to automatically adjust insulin delivery, eliminating the need for mealtime interaction. The study will enroll up to 350 adults across 40 U.S. sites. Insulet's innovation is intended to improve glycemic outcomes with less burden for users, particularly in primary care settings where most type 2 diabetes patients are managed. The company plans to submit a 510(k) filing to the FDA in 2027 and launch the system in 2028.
Trendline Trendline
AI-Driven Apps Transform Nursing with Gig Work Model

AI-Driven Apps Transform Nursing with Gig Work Model

AI-Driven Apps Transform Nursing with Gig Work Model
Rapid Read Rapid Read
Uruguayan Doctor's EB-2 NIW Petition Approved to Enhance U.S. Healthcare Access

Uruguayan Doctor's EB-2 NIW Petition Approved to Enhance U.S. Healthcare Access

A medical doctor from Uruguay has successfully secured an EB-2 National Interest Waiver (NIW) petition, allowing him to work in the United States. The approval was granted by the United States Citizenship and Immigration Services (USCIS) after a Request for Evidence (RFE) was addressed. The doctor's initiative focuses on using artificial intelligence and data science to improve healthcare access in underserved U.S. communities. His approach aims to tackle the significant healthcare access gaps in rural and underserved areas, where provider shortages and geographic barriers hinder timely medical care. By leveraging telemedicine platforms and data analysis tools, the doctor plans to facilitate remote patient consultations, particularly in regions with limited access to hospitals and specialists.
Rapid Read Rapid Read
AI-Powered Conversation Intelligence Aims to Reduce Healthcare No-Show Costs

AI-Powered Conversation Intelligence Aims to Reduce Healthcare No-Show Costs

Healthcare systems are increasingly utilizing AI-powered conversation intelligence to address the significant issue of patient no-shows, which cost the industry up to $150 billion annually. This technology analyzes patient calls to extract valuable insights, helping healthcare providers understand and mitigate barriers to care. By identifying patterns such as scheduling difficulties and unanswered insurance questions, healthcare organizations can improve patient access and reduce missed appointments. The use of AI in call scoring allows for rapid analysis of patient communications, enabling targeted coaching for staff and better patient interaction management. Companies like Marchex are developing tools to monitor AI performance in handling patient calls, ensuring that AI-driven interactions are as effective as those managed by human agents.
Rapid Read Rapid Read
Federal Judge Questions Legality of Hemp-Marijuana Reimbursement Program for Medicare

Federal Judge Questions Legality of Hemp-Marijuana Reimbursement Program for Medicare

A federal district court in Washington, D.C. is reviewing a case challenging the Centers for Medicare & Medicaid Services (CMS) over its hemp-marijuana reimbursement program. The case, Smart Approaches to Marijuana v. Kennedy, questions whether CMS exceeded its authority by implementing a program that reimburses cannabinoid products for Medicare beneficiaries without public rule-making or FDA involvement. The program, which began on April 1, 2026, allows organizations to provide hemp-derived products and receive up to $500 per beneficiary annually. The court is considering whether the program's implementation without FDA validation or public input violates statutory requirements.
Rapid Read Rapid Read
Federal Court Reviews CMS Hemp-Marijuana Reimbursement Program Amid Legal Challenge

Federal Court Reviews CMS Hemp-Marijuana Reimbursement Program Amid Legal Challenge

A federal district court in Washington, D.C. is reviewing a legal challenge against the Centers for Medicare & Medicaid Services (CMS) regarding its hemp-marijuana reimbursement program. The case, Smart Approaches to Marijuana v. Kennedy, questions whether CMS exceeded its authority by implementing a reimbursement incentive for hemp-derived cannabinoid products without public rule-making or FDA involvement. The program, which began on April 1, 2026, allows participating organizations to provide these products to Medicare beneficiaries, with potential reimbursements of up to $500 per beneficiary annually. The court is considering whether the CMS's actions align with statutory requirements and if the program can proceed without traditional regulatory processes.
Rapid Read Rapid Read
Senators Propose Extension of Cost-Based Payments for Rural Hospitals to Ensure Financial Stability

Senators Propose Extension of Cost-Based Payments for Rural Hospitals to Ensure Financial Stability

Senators Chuck Grassley and Michael Bennet have introduced a legislative proposal to extend the Rural Community Hospital Demonstration program for an additional five years. This program, which has been in place since 2004, provides cost-based reimbursement to rural hospitals that do not qualify as Critical Access Hospitals. The extension aims to support hospitals with fewer than 51 beds and 24-hour emergency services by offering higher Medicare payments for inpatient services. The program is crucial for maintaining financial viability, as evidenced by the Centers for Medicare and Medicaid Services' evaluation, which showed significant financial benefits for participating hospitals. The proposal has garnered bipartisan support, with 14 other senators co-sponsoring the extension.